| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/26/2006 | US20060240037 Methods and compositions for the treatment and prevention of degenerative joint disorders |
| 10/26/2006 | US20060240024 T cell regulation |
| 10/26/2006 | US20060240019 Antagonists of HMG1 for treating inflammatory conditions |
| 10/26/2006 | US20060240014 Methods and compounds for the treatment of vascular stenosis |
| 10/26/2006 | US20060240011 Use of nf-kappa b inhibitors for the treatment of mastitis |
| 10/26/2006 | US20060240007 Method for treating dementia or Alzheimer's disease |
| 10/26/2006 | US20060240003 Humanised antibodies to the epidermal growth factor receptor |
| 10/26/2006 | US20060240000 Combination treatments for allergic disease comprising administering an anti-IgE antibody and antiallergic compound |
| 10/26/2006 | US20060239999 Preventive and/or therapeutic drugs for asthma |
| 10/26/2006 | US20060239992 Methods and compositions for the inhibition of growth of infectious aspergillus fumigatus and other mycotic organisms in the gut of mammalian and avian species |
| 10/26/2006 | US20060239990 Protein Arginine N-Methyltransferase 2 (PRMT-2) |
| 10/26/2006 | US20060239961 Hydrolytically degradable alkylene oxide based polymers |
| 10/26/2006 | US20060239959 Method for treating hypercholesterolemia with polyallylamine polymers |
| 10/26/2006 | US20060239957 Using extract of olive leaves |
| 10/26/2006 | US20060239936 Delivery of anti-migraine compounds through an inhalation route |
| 10/26/2006 | US20060239935 Compositions for inhalation |
| 10/26/2006 | US20060239934 Superior control of blood glucose in diabetes treatment |
| 10/26/2006 | US20060239932 Pharmaceutical formulations comprising magnesium stearate |
| 10/26/2006 | US20060239929 Use of a clobetasol spray formulation to treat psoriasis |
| 10/26/2006 | US20060239928 Transmucosal administration of drug compositions for treating and preventing disorders in animals |
| 10/26/2006 | US20060239927 Drug for airway administration |
| 10/26/2006 | US20060239926 Specific high-relaxivity compounds |
| 10/26/2006 | US20060239915 Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases |
| 10/26/2006 | DE4244539B4 Duale Inhibitoren der No-Synthese und Cyclooxygenase, Verfahren zu ihrer Herstellung und therapeutische Präparate, die sie enthalten Dual inhibitors of NO synthesis and cyclooxygenase, processes for their preparation and therapeutic compositions containing them |
| 10/26/2006 | DE20321278U1 Cosmetic or dermatological preparation in water-in-oil emulsion form, useful to treat e.g. neurodermatitis, dyskeratoses and scars, comprises phytosterols and optionally additional materials |
| 10/26/2006 | DE20321277U1 Cosmetic/dermatological preparation in form of oil-in water emulsion, useful for treating e.g. neurodermatitis and skin aging, comprises phytosterol groups, oil components and additional materials |
| 10/26/2006 | DE19542786B4 Verbindungen mit bakterizider und/oder antimykotischer Aktivität, Herstellungsverfahren, Mittel und Mikroorganismenstamm Compounds with bactericidal and / or antifungal activity, manufacturing processes, resources and microorganism strain |
| 10/26/2006 | DE10242476B4 Antibiotikum-/Antibiotika-Polymer-Kombination Antibiotic / polymer combination |
| 10/26/2006 | DE102005020105A1 New thiazolidinone compounds are polo-like kinase inhibitors, useful for the preparation of medicament to treat e.g. cancer, autoimmune disease, cardiovascular disease stenosis and infection disease |
| 10/26/2006 | DE102005020104A1 New thiazolidinone compounds are polo-like kinase inhibitors, useful for the preparation of medicament to treat e.g. cancer, autoimmune disease, cardiovascular disease stenosis and infection disease |
| 10/26/2006 | DE102005019458A1 Composition, useful in the preparation of pellets and the multi-particular-presentation form, comprises cefuroximaxetil and carrageenan of the group of lambda carrageenan, tau carrageenan and kappa carrageenan |
| 10/26/2006 | DE102005019181A1 New indene compound are peptide-deformylase inhibitors useful e.g. to treat or prevent diseases mediated by metalloproteinase activity and peptide-deformylase activity |
| 10/26/2006 | DE102005019094A1 New aza-heterocyclic compounds are tyrosine kinase inhibitor useful to prevent and/or treat cancer, tumor growth, tumor angiogenesis, arteriosclerosis, diabetic retinopathy and inflammation diseases |
| 10/26/2006 | DE102005018887A1 Topical pain therapy, useful to treat pain of calcified fascia and tendons, comprises using topical formulation containing decalcified phosphocitrate, injecting into calcium deposits and working effectively at place of application |
| 10/26/2006 | DE102005018690A1 Imino-oxazolidine und ihre Verwendung Imino-oxazolidines and their use |
| 10/26/2006 | DE102005018389A1 Azolderivate als Inhibitoren von Lipasen und Phospholipasen Azole derivatives as inhibitors of lipases and phospholipases |
| 10/26/2006 | DE102005018191A1 Substituierte zyklische Harnstoff-Derivate und deren Verwendung zur Herstellung von Arzneimitteln Substituted cyclic urea derivatives and their use for the preparation of medicaments |
| 10/26/2006 | DE102005018184A1 New phenyl ester compounds useful as antioxidants, for the reduction of skin aging, or for the prevention/treatment of inflammations, allergies and irritations of skin |
| 10/26/2006 | DE102005018026A1 New substituted styrol stereoisomers are glucocorticoid receptor ligands useful for the treatment of e.g. inflammatory diseases, lung diseases, rheumatic diseases, autoimmune diseases, joint disorders and gastrointestinal disorders |
| 10/26/2006 | DE102005017116A1 Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP) Inhibitors of inhibitors of apoptosis proteins (IAP) |
| 10/26/2006 | DE10163667B4 Verwendung von Desoxypeganin zur Behandlung der klinischen Depression Use of deoxypeganine for the treatment of clinical depression |
| 10/26/2006 | CA2851079A1 Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy |
| 10/26/2006 | CA2675652A1 Dosage forms of risedronate |
| 10/26/2006 | CA2646257A1 Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients |
| 10/26/2006 | CA2643677A1 Compositions of novel opioid compounds and method of use thereof |
| 10/26/2006 | CA2618721A1 Elimination of heterogeneous or mixed cell population in tumors |
| 10/26/2006 | CA2610446A1 Nitrogen-containing heterocyclic compound |
| 10/26/2006 | CA2606301A1 Azole derivatives in the form of lipase and phospholipase inhibitors |
| 10/26/2006 | CA2606288A1 Subtituted heteroaryl cb1 antagonists |
| 10/26/2006 | CA2606270A1 Amphiphilic polymers and methods of use thereof |
| 10/26/2006 | CA2606174A1 Design and synthesis of novel tubulin polymerization inhibitors: benzoylphenylurea (bpu) sulfur analogs |
| 10/26/2006 | CA2605967A1 Topiramate compositions for treatment of headache |
| 10/26/2006 | CA2605960A1 Nutritional supplement for hiv patients |
| 10/26/2006 | CA2605778A1 Fused heterocyclic compound |
| 10/26/2006 | CA2605512A1 Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secondary rna structure. |
| 10/26/2006 | CA2605492A1 Iminooxazolidines and their use |
| 10/26/2006 | CA2605419A1 Compositions for the treatment of neoplasms |
| 10/26/2006 | CA2605414A1 Nutritional supplement with colostrum and epa or dha or gla |
| 10/26/2006 | CA2605401A1 Compositions and methods for modulating interleukin-10 |
| 10/26/2006 | CA2605385A1 Combination of ferroquine and artesunate for the treatment of malaria |
| 10/26/2006 | CA2605332A1 Method and composition for inhibiting cell proliferation and angiogenesis |
| 10/26/2006 | CA2605300A1 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity |
| 10/26/2006 | CA2605210A1 Nutritional supplement for a category of hiv patients |
| 10/26/2006 | CA2605180A1 Controlled delivery dosage form of tramadol and gabapentin |
| 10/26/2006 | CA2605161A1 Dihydrothienopyrimidines for the treatment of inflammatory diseases |
| 10/26/2006 | CA2605150A1 Combination formulation |
| 10/26/2006 | CA2605144A1 Substituted cyclic urea derivatives and the use thereof as vanilloid receptor 1 modulators |
| 10/26/2006 | CA2605138A1 Formulations of quaternary ammonium neuromuscular blocking agents |
| 10/26/2006 | CA2605078A1 Plant-derived elastin binding protein ligands and methods of using the same |
| 10/26/2006 | CA2605075A1 2 - pyrrolidone derivatives and their uses for the treatment of inflammatory conditions and pain |
| 10/26/2006 | CA2605059A1 Oxindole compounds and their uses as therapeutic agents |
| 10/26/2006 | CA2605020A1 Method for treating inflammatory bowel disease (ibd) by an anti-cd20 antibody |
| 10/26/2006 | CA2605010A1 Uronic acid and probiotics |
| 10/26/2006 | CA2604956A1 Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient |
| 10/26/2006 | CA2604943A1 Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
| 10/26/2006 | CA2604942A1 2-amino-quinaz0lin-5-ones |
| 10/26/2006 | CA2604920A1 Novel compounds useful for bradykinin b1 receptor antagonism |
| 10/26/2006 | CA2604912A1 Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci |
| 10/26/2006 | CA2604907A1 Combination cancer therapy with bis(thiohydrazide) amide compounds |
| 10/26/2006 | CA2604821A1 2 -aminocarbonyl substituted piperazine or diaza-cyclic compounds as apoptosis protein inhibitor (iap) modulators |
| 10/26/2006 | CA2604805A1 Pyrrolobenzodiazepines |
| 10/26/2006 | CA2604787A1 Quinobenzoxazine analogs and methods of using thereof |
| 10/26/2006 | CA2604778A1 Anti-inflammatory and/or analgesic composition for the intestine comprising branched maltodextrins |
| 10/26/2006 | CA2604719A1 Substituted 2-amin0alkylthi0-benzimidaz0les and use thereof for reducing blood sugar levels |
| 10/26/2006 | CA2604581A1 Combinations, methods and compositions for treating cancer |
| 10/26/2006 | CA2604515A1 Toll-like receptor 14 (tlr14 ) and use thereof |
| 10/26/2006 | CA2604393A1 Methods and compositions for treating or preventing cancer |
| 10/26/2006 | CA2604295A1 Roflumilast for the treatment of pulmonary hypertension |
| 10/26/2006 | CA2604218A1 Pyrazole derivatives as progesterone receptor antagonists |
| 10/26/2006 | CA2603920A1 Pharmacological treatment for sleep apnea |
| 10/26/2006 | CA2603876A1 N-alkyl-azacycloalkyl nmda/nr2b antagonists |
| 10/26/2006 | CA2603833A1 Utilisation de l'azithromycine pour la fabrication d'un medicament de traitement des infections oculaires |
| 10/26/2006 | CA2603757A1 Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| 10/26/2006 | CA2603518A1 Nutrient composition for promoting collagen production |
| 10/26/2006 | CA2603314A1 Methods of increasing natural killer cell activity for therapy |
| 10/26/2006 | CA2602610A1 Benzimidazole compound |
| 10/26/2006 | CA2602247A1 Piperazine-substituted benzothiophenes for treatment of mental disorders |
| 10/26/2006 | CA2601979A1 2,3 substituted pyrazine sulfonamides |
| 10/26/2006 | CA2600774A1 Pharmaceutically active diazepanes |
| 10/26/2006 | CA2599618A1 Use of lactobacillus rhamnosus gg in combination with a long chain polyunsaturated fatty acid for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant |